GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing
Highlights Broad National Support for Domestic Vaccine Resilience and Role of MVA Platform in Public Health Preparedness
ATLANTA, GA - May 29, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, voiced strong support for the newly announced bipartisan initiative by U.S. Senators Joni Ernst (R-IA) and Lisa Blunt Rochester (D-DE) to onshore the manufacturing of critical pharmaceutical supplies. The Critical Infrastructure Manufacturing Feasibility Act seeks to reduce reliance on foreign sources for key medical products - directly aligning with GeoVax's mission to rebuild U.S.-based vaccine manufacturing and strengthen national preparedness.
'We are seeing a unified, national groundswell - from Congress, the White House, HHS, FDA, BARDA, and commissions like NSCEB - calling for the onshoring of America's vaccine manufacturing base,' said David Dodd, Chairman and CEO of GeoVax. 'GeoVax is purpose-built to answer that call, with a clinically validated MVA platform, a domestic manufacturing strategy, and a focus on pandemic responsiveness and protection of the immunocompromised.'
Rebuilding U.S. Biomanufacturing Through Coordinated Federal Action
The Senate initiative complements a cascade of government actions to bring the manufacturing of essential medical countermeasures - including vaccines - back to U.S. soil including:
These actions reflect growing bipartisan recognition that national health security depends on resilient, scalable domestic vaccine capacity.
MVA Technology: Protecting the Immunocompromised with Durable, Multi-Antigen Vaccines
GeoVax's MVA platform supports a pipeline of multi-antigen vaccines, including GEO-CM04S1 (COVID-19), primarily targeted to address the current unmet needs inducing broad T-cell and antibody responses among immunocompromised individuals, overcoming the limitations of single-antigen vaccines.
GeoVax's MVA vaccines align with FDA and HHS goals to advance diversified, multi-antigenic strategies that provide broader, longer-lasting protection across high-risk groups.
Enabling U.S. Biomanufacturing Through Equip-A and BARDA RRPV: A Roadmap to Rapid, U.S.-Based Vaccine Production
GeoVax's progressing advanced MVA manufacturing process is anticipated to eliminate the need for pathogen-free eggs and leverage a continuous avian cell line system, directly supporting the objectives of the federal government's EQUIP-A-Pharma initiative. This HHS-ASPR-DARPA program aims to create agile, point-of-care pharmaceutical production capabilities using modular, AI-driven platforms.
Additionally, GeoVax's proposal - 'Innovation in Clinical Manufacturing of MVA-Vectored COVID-19 Vaccines' - was selected by BARDA's Rapid Response Partnership Vehicle (RRPV), pending funding availability. The program is designed to accelerate the scale-up of advanced U.S.-based MVA vaccine manufacturing. The proposal is designed to:
If funded, this effort is expected to create a scalable, resilient domestic manufacturing platform essential for the rapid deployment of MVA-based vaccines like GEO-CM04S1 (COVID-19) and GEO-MVA (Mpox/smallpox).
Platform Alignment with National Priorities
GeoVax's MVA-based vaccines embody the shift in U.S. public health strategy away from single-antigen platforms and toward multi-antigen, durable, and safe alternatives. These vaccines are specifically engineered to meet the needs of high-risk populations - including the 40+ million immunocompromised Americans who may not respond effectively to mRNA and other vaccines that focus primarily on inducing antibody immunity.
GeoVax's U.S.-controlled MVA platform addresses key government objectives:
Call for Continued Bipartisan Momentum
'With renewed bipartisan focus on U.S. medical independence, there is no better time to invest in American-homegrown vaccine innovation,' added Dodd. 'We urge lawmakers and federal agencies to continue supporting domestic capacity, biodefense readiness, and equitable access to advanced medical countermeasures to protect both our national security and our most vulnerable populations.'
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Company Contact:
[email protected]
678-384-7220
Investor Relations Contact:
[email protected]
212-698-8696
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Who won the first NYC Democratic mayoral primary debate?
Ex-Gov. Andrew Cuomo won Wednesday night's Democratic mayoral primary debate — because his opponents' relentless attacks did more to elevate him than drag him down, a Post panel of veteran campaign strategists said. The thrice-elected Democrat took some gut punches, but there was no knockout blow or major blunder on his part, the political analysts on both sides of the aisle said. 'I tuned in to see a mayoral debate, not a debate about Andrew Cuomo,' quipped campaign strategist Ken Frydman of the nine-person debate moderated by NBC 4 NY and Politico. 'By making Andrew the debate, they elevated him,' said Frydman. Because Cuomo was constantly under fire, he got more airtime to respond to each jab and by default dominated the more than two-hour debate, the political experts said. 'Everyone tried to land a punch on Andrew Cuomo, but failed,' said campaign strategist O' Brien 'OB' Murray. 'The first 20 minutes gave Cuomo the center stage, literally and figuratively,' he said, referring to the ex-gov's position in the middle of the group of candidates standing on the dais at 30 Rockefeller Center. 'He handled the attacks and was able to deflect. They actually gave him more airtime than they should have,' Murray said. Republican campaign strategist Bill O'Reilly said the verbal pummeling Cuomo received from most of his eight primary rivals does not alter his status as the front-runner for the Democratic nomination. 'It was Andrew Cuomo vs. the Lilliputians, and the Lilliputians fell short. That's the bottom line,' O'Reilly said. 'Someone needed to trip up the former governor to slow his momentum, but it was clear from the jump that wouldn't happen. Cuomo hasn't lost a step since leaving Albany, and the field lacked the skill to crack him.' Cuomo also counter-attacked, taking shots at his biggest threats in the polls — 33-year-old Democratic socialist Zohran Mamdani, a state Assembly member from Queens, and City Comptroller Brad Lander. The former governor delivered the best line when he said, '[President] Trump would go through Mamdani like a hot knife through butter,' O'Reilly noted. Frydman said the candidates and moderators did force Cuomo to squirm to defend his record as governor, including his controversial nursing home policy during the COVID-19 pandemic and his approval of the unpopular 2019 bail reforms. They also tried to make him answer for the spate of sexual misconduct accusations leveled against him — which he denied, but which forced his resignation in 2021. Some of the other candidates had 'breakout moments' — including former Bronx Assemblyman Michael Blake, City Council Speaker Adrienne Adams and Mamdani, said political adviser Yvette Buckner. 'That will have voters wanting to learn more about them, their policies and their candidacy,' she said. Frydman too said Adams' performance 'moved the needle' for her campaign, which has been slow to gain momentum despite support from state Attorney General Letitia James. 'She introduced herself to Democratic voters well enough on substance to move up in ranked-choice voting,' he said. But Cuomo's comfortable lead over second-place Mamdani in recent polls should hold, Frydman said. O'Reilly agreed, but said Mamdani remains Cuomo's 'greatest threat' for the nomination in the June 24 primary. Two of the panelists agreed that Lander is competent, but his persona didn't translate on TV. 'He oozes insincerity in a car-salesman-type way,' O'Reilly said. But he said Brooklyn state Sen. Zellnor Myrie's sincerity came across 'easily,' calling him a rising star in the Democratic Party. Murray concurred, saying Lander has a 'stage presence for radio and a delivery for print. He confirmed why he has his wife and daughter on videos, instead of himself.' Another candidate, former city Comptroller Scott Stringer, who previously ran for mayor in 2021, didn't break through, the panelists said. 'Stringer was Stringer — flat, and after a second run for mayor, still didn't connect to voters,' Murray said. All but two of the Democratic contenders will debate again on June 12, save for Blake and state Sen. Jessica Ramos, who failed to meet the campaign funding threshold. Nine days of early voting will precede the primary, beginning on June 14.
Yahoo
2 hours ago
- Yahoo
Artists who got almost $1,500 a month under a basic income pilot say their work improved
Ireland's basic income pilot program for the arts ends in August. For three years, 2,000 artists and creative arts workers received about $370 a week. Recipients said the stipend overall improved their daily lives. For about 2,000 artists and creative arts workers in Ireland, a weekly stipend provided through a basic income program has been a lifeline for years. Now, it's almost over. The pilot program began in 2022 under Catherine Martin, Ireland's former minister for tourism and culture. Martin allocated about $28 million to the arts sector following the COVID-19 pandemic. Participants were randomly chosen and given an unconditional stipend of €325, or about $370, weekly for three years. During that time, participants met periodically via Zoom to discuss how the additional income had affected their livelihoods, careers, and ability to meet basic needs. The final session was held this month before the program's conclusion in August. Artists and cultural workers who attended the session grappled with what their lives would look like after August, but they hoped government officials would extend the program. "We need no further pilots. People need a UBI now to face and deal with the many social, economic, and ecological crises of our world," Reinhard Huss, the organizer of UBI Lab Leeds, which sponsored the event alongside Basic Income Ireland, UBI Lab Arts, and UBI Lab Network, told Business Insider. New developments in AI are reshaping the job market, replacing some entry-level positions. Tech industry leaders like Elon Musk and OpenAI CEO Sam Altman have said implementing a universal basic income will be essential in the near future when AI supplants jobs in most industries. A universal basic income offers an entire population recurring, unconditional payments regardless of an individual's socioeconomic status. Ireland's program, like many others in the United States, is a guaranteed basic income, which targets certain segments of the population for a set period of time. Jenny Dagg, a sociologist lecturing at Ireland's Maynooth University, authored a new report that provides insights into participants' reactions to the program. She gathered data from over 50 of the 2,000 recipients. Although the report outlined nearly a dozen key impacts reported by program recipients, Dagg highlighted five major takeaways during the Zoom session. Dagg said that recipients who received money from the program reported more stability and "significantly reduced" financial stress. It relieved their anxiety about fulfilling their basic needs. Participating in the pilot program also allowed artists to re-prioritize how they spend their time and what they choose to focus on. "The opportunity to focus more on their specific creative interests opened new possibilities and career trajectories," the report said. Artists said the added income allowed them to spend more time "researching, experimenting, taking risks, and failing," which has improved the quality of their work. Artists, the report said, also felt more confident in themselves and their work during the program. "Many recipients talk of feeling empowered, of being in control of the choices within their lives, and envisioning a viable career path longer-term," the report said. Recipients even reported better mental health, which led to improved sleep quality and lowered stress levels. With the end of the program fast approaching, recipients of the weekly payment are reckoning with what how their lives might change. "Across art forms, recipients report concerns about financial stability and sustaining the momentum of their careers when, or if, the basic income scheme ends," Dagg's report said. This month, Basic Income Ireland called on the government to immediately implement a universal and unconditional basic income for the country. A spokesperson for the UBI Lab Network said the pilot program's success shows that basic income is a viable option. The campaign group shared a proposal for introducing a universal basic income to Ireland. "As the pilot shows, basic income works and people need a UBI now to face and deal with the many social, economic, and ecological crises of our world. The Network will continue to help demonstrate basic income within communities and show how it is a sustainable policy," the statement said. Patrick O'Donovan, Ireland's minister for arts and culture, said he would evaluate the data collected throughout the pilot program and create proposals for the government regarding the next steps. "I am heartened by the responses of the Basic Income recipients in this paper," O'Donovan said in the May report. "This research will add to the evaluation being conducted by my department, which to date clearly shows that the Basic Income Pilot has been an effective support for the artists in receipt of it." Read the original article on Business Insider
Yahoo
2 hours ago
- Yahoo
Hispanic Heritage Council receives $7M for construction of cultural institute
BUFFALO, N.Y. (WIVB) — The Hispanic Heritage Council of Western New York will receive $7 million from New York State to complete the construction of its cultural institute on Buffalo's West Side, Gov. Kathy Hochul announced Sunday. The council's plans for the multi-use 37,000-square-foot facility on the corner of Niagara and Hudson Streets was first announced in 2019, but it has since faced delays due to COVID-19. Hochul described the investment as a 'gap-filling' initiative for phase two of the institute, which will serve as a hub for Hispanic history, arts and community. The $30 million facility broke ground in September 2023 at the beginning of Hispanic Heritage Month. The council plans for the institute to house a museum, 150-seat performing arts theater, event spaces, cafe, media center and learning labs. 'We are deeply grateful to Governor Hochul for her unwavering support of the Hispanic Heritage Cultural Institute. This historic investment is not just a milestone for the Buffalo Hispanic community — it's a gift to all of Western New York,' said Casimiro Rodriguez, the council's president and founder. 'As the first of its kind, this institute will serve as a vibrant hub for arts, culture, education, and heritage, drawing visitors from near and far, including our Canadian neighbors. It will enrich our region's cultural landscape and strengthen our identity as a welcoming and diverse community. The future is bright, and we are filled with hope and gratitude as we take this giant step forward together.' Hochul said the previous announcement in 2023 of a $5 million grant, along with additional funding, will continue to help with the completion of the project's second phase and grand opening. 'New Yorkers of Puerto Rican heritage have been an integral part of our state's cultural fabric for generations,' Hochul said. 'We are honored to make bold investments that will empower organizations to expand and thrive, ensuring that the vibrant presence of Puerto Rican culture in New York State remains a cherished aspect of our state's identity.' The council also received $1 million in federal funding in August 2023 for construction. Katie Skoog joined the News 4 team in April 2024. She is a graduate from the University at Buffalo. You can view more of her work here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
